Acute Myelomonocytic Leukemia

Search Trials
A Study to Evaluate the Efficacy and Safety of Maralixibat in Subjects With Progressive Familial Intrahepatic Cholestasis (MARCH-PFIC)
Status:
Recruiting
Last Changed:
Aug 7, 2019
First Changed:
Apr 5, 2019
Disease(s):
Progressive Familial Intrahepatic Cholestasis (PFIC)
Intervention(s):
MaralixibatPlacebo
A Placebo-controlled Study of Maralixibat (SHP625) in Pediatric Subjects With Progressive Familial Intrahepatic Cholestasis (PFIC)
Status:
Withdrawn
Last Changed:
Mar 18, 2019
First Changed:
Nov 27, 2017
Disease(s):
Progressive Familial Intrahepatic Cholestasis (PFIC)
Intervention(s):
MaralixibatPlacebo
Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes
Status:
Completed
Last Changed:
Sep 30, 2013
First Changed:
Dec 8, 2004
Disease(s):
Accelerated Phase Chronic Myelogenous Leukemia
Intervention(s):
tanespimycincytarabine
Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia
Status:
Active, not recruiting
Last Changed:
Dec 4, 2018
First Changed:
Jun 25, 2012
Disease(s):
Acute Myeloid Leukemia
Intervention(s):
CytarabineDaunorubicin HydrochlorideDecitabineLaboratory Biomarker AnalysisPharmacological Study
Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
Status:
Completed
Last Changed:
Feb 2, 2017
First Changed:
Apr 12, 2006
Disease(s):
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Intervention(s):
AzacitidineEntinostatLaboratory Biomarker Analysis

Connect. Empower. Inspire.